Clinical trials: Healthy Volunteers Type 2 Diabetes
Obesity & Overweight, Type 2 Diabetes
A Food-Effect Study of CX11 in Healthy Participants
This study is to evaluate the food effect (FE) on the PK of 200 mg CX11 in healthy participants
- Trial name
- NCT07349381
- Testing
- CX11 (VCT220)
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Chronic Kidney Diseases, Diabetes Mellitus, Type 2
Effect of Acute Fructose Load in Human
The metabolism of the monosaccharide fructose is less controlled than the metabolism of glucose, which will result in the metabolic product uric acid.
- Trial name
- NCT03157960
- Testing
- Blueberry drink, Blueberry and pizza, Soft beverage
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Diabetes, Diabetes Mellitus, Type 2
A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to assess the expected biological equivalence between two formulations of insulin degludec/liraglutide (IDegLira) with identical active ingredient in healthy volunteers.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01916174
- Testing
- insulin degludec/liraglutide
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect of drug) of NNC 0148-0000-0362 as tablets in healthy…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01597713
- Testing
- NNC 0148-0000-0362, insulin glargine
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects
The primary objective of this study is to determine the absolute bioavailability of SRT2104 as a 250 mg suspension, and to define the intravenous pharmacokinetics of SRT2104.
- Trial name
- NCT00937872
- Testing
- 250 mg SRT2104 Suspension, Carbon-14 radio-labeled SRT2104
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Sirtris, a GSK Company
Healthy, Type 2 Diabetes Mellitus
Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of multiple oral doses of GMC-252-L-Lysine salt (GMC-252) in healthy subjects and type 2 diabetics.
- Trial name
- NCT02744820
- Testing
- GMC-252-L-Lysine Salt
- Where
- 2 sites in United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Genmedica Therapeutics S.L.
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers
This study is a randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose-escalation phase I clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic…
- Conditions
- Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07801313
- Testing
- MWN105
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Type2 Diabetes
DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients
An Open-Label Phase I Study to Assess the Safety and Tolerability Profile of Three Escalating Doses of DCB-DM101 in Healthy Volunteers and Optimum Dose of DCB-DM101 as Add-on Treatment in Type 2 Diabetes Mellitus (T2DM) Patients
- Trial name
- NCT03033433
- Testing
- DCB-DM101
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- VitNovo, Inc.
Diabetes Mellitus, Type 2
A Drug Interaction Study of Simvastatin and Albiglutide
This open-label study evaluates the pharmacokinetics of simvastatin when coadministered with albiglutide in healthy adult subjects.
- Trial name
- NCT01147692
- Testing
- simvastatin plus albiglutide
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Participants
A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants
The purpose of this study is to assess the impact of multiple doses of itraconazole on the pharmacokinetics (PK) of AZD5004 in healthy participants (Part A), and to assess the impact of multiple doses of AZD5004 on the PK of…
- Trial name
- NCT06942936
- Testing
- AZD5004, Itraconazole, EE/LNG
- Where
- 2 sites in United States, Germany
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.
The study is comparing the new medicine NNC9204-1513 with a standard therapy of glucagon (GlucaGen®). This is the first time NNC9204-1513 is given to humans.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03444467
- Testing
- NNC9204-1513, Glucagon
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Participants
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants
The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.
- Trial name
- NCT07534592
- Testing
- Elecoglipron, Atorvastatin, Rosuvastatin
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Drug-drug Interaction Study (CKD-501, Ketoconazole)
The purpose of this study is to assess the effect of Ketoconazole on the pharmacokinetic characteristics of CKD-501 in healthy subject.
- Trial name
- NCT01330563
- Testing
- CKD-501, Ketoconazole
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2
A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes
The aim of this trial is to evaluate the safety of single doses of a study drug known as LY3325656 that is given orally to healthy participants and participants with type 2 diabetes.
- Trial name
- NCT03115099
- Testing
- LY3325656, Liraglutide, Sitagliptin
- Where
- 2 sites in Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hypertension, Diabetes Mellitus, Type 2
A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.
The study was designed to evaluate the safety and pharmacokinetic interaction between THP-00101 and THP-00102 in healthy adult volunteers.
- Trial name
- NCT06063109
- Testing
- THP-00101 (Dapagliflozin) 10mg, THP-00102 (Telmisartan) 80mg
- Where
- South Korea
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- THPharm Corp.
Diabetes Mellitus, Type 2
Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes
This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients…
- Trial name
- NCT00633997
- Testing
- Vildagliptin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus
This is a double blind, randomised, placebo controlled, single dose escalation, first-time-in-human, 5-way crossover study to assess the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of ascending doses of…
- Trial name
- NCT01571661
- Testing
- GSK189075A
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers
SP2086 is a novel inhibitor of Dipeptide base peptidase 4, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia.
- Trial name
- NCT02826044
- Testing
- SP2086
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)
This study is designed to investigate the food-effects on FDC(gemigliptin/metformin HCl sustained release) 50/1000mg(25/500mg x 2tablets)
- Trial name
- NCT01747083
- Testing
- FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences